Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo

[1]  K. Nakai,et al.  [Controlling signal transduction with synthetic ligands]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[2]  A. Awasthi,et al.  Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses , 2004, Nature Medicine.

[3]  D. Pardoll,et al.  Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.

[4]  C. Ahonen,et al.  Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN , 2004, The Journal of experimental medicine.

[5]  S. Nagata,et al.  Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. , 2003, The Journal of biological chemistry.

[6]  R. Zamoyska,et al.  Regulation of peripheral T-cell homeostasis by receptor signalling. , 2003, Current opinion in immunology.

[7]  W. Daniel,et al.  Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia , 2003, Stroke.

[8]  E. Pamer,et al.  Feedback regulation of pathogen-specific T cell priming. , 2003, Immunity.

[9]  D. Ridgway.  The First 1000 Dendritic Cell Vaccinees , 2003, Cancer investigation.

[10]  Ranjeny Thomas,et al.  Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. , 2003, Immunity.

[11]  Ranjeny Thomas,et al.  CD40 Ligation Conditions Dendritic Cell Antigen-Presenting Function Through Sustained Activation of NF-κB1 , 2002, The Journal of Immunology.

[12]  R. Hynes,et al.  CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism , 2002, Nature Medicine.

[13]  Michael A. Barry,et al.  The Role of T Cell Antagonism and Original Antigenic Sin in Genetic Immunization , 2002 .

[14]  C. Uyttenhove,et al.  CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization. , 2002, Cancer immunity.

[15]  R. Darnell,et al.  Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells , 2001, Nature Immunology.

[16]  B. Coombes,et al.  Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines. , 2001, Immunology letters.

[17]  T. Clackson,et al.  Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers , 2001, Journal of clinical pharmacology.

[18]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[19]  J. Gribben,et al.  Phase I study of recombinant human CD40 ligand in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Kaykas,et al.  CD40 and LMP‐1 both signal from lipid rafts but LMP‐1 assembles a distinct, more efficient signaling complex , 2001, The EMBO journal.

[21]  H. Waldmann,et al.  Regulation of CD40 function by its isoforms generated through alternative splicing. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Reis e Sousa,et al.  Dendritic cells as sensors of infection. , 2001, Immunity.

[23]  F. Sallusto,et al.  Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. , 2000, Science.

[24]  A. Sher,et al.  CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. , 2000, Immunity.

[25]  F. Sallusto,et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.

[26]  A. Siegbahn,et al.  Role of Platelet P-Selectin and CD40 Ligand in the Induction of Monocytic Tissue Factor Expression , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  R. Crystal,et al.  Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. , 2000, Blood.

[28]  Claudia Mauri,et al.  Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process , 2000, Nature Medicine.

[29]  Joanna M. Roberts,et al.  CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity1 , 2000, The Journal of Immunology.

[30]  Jianping Yang,et al.  CD8 T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity , 2000 .

[31]  D. Mukhopadhyay,et al.  Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. , 2000, Blood.

[32]  A. Sher,et al.  Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. , 1999, Immunity.

[33]  M. Daemen,et al.  Requirement for CD154 in the progression of atherosclerosis , 1999, Nature Medicine.

[34]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[35]  M. Kehry,et al.  CD40 Signaling through Tumor Necrosis Factor Receptor-associated Factors (TRAFs) , 1999, The Journal of Biological Chemistry.

[36]  Shannon R. Magari,et al.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[38]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[39]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[40]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[41]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[42]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[43]  G. Thomas,et al.  Nuclear localization of RelB is associated with effective antigen-presenting cell function. , 1997, Journal of immunology.

[44]  M. Foti,et al.  Retroviral immortalization of phagocytic and dendritic cell clones as a tool to investigate functional heterogeneity. , 1994, Journal of immunological methods.

[45]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.